Investigating how IL-27R signaling affects immune responses in liver cancer
IL-27R signaling as a negative regulator of innate and adaptive anti-cancer immunity in hepatocellular carcinoma
This study is looking at how a specific signaling pathway in the immune system affects liver cancer, hoping to find new ways to help the body fight the disease better, which could lead to better treatments for patients with liver cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10894816 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of IL-27R signaling in liver cancer, specifically hepatocellular carcinoma (HCC). The study aims to explore how this signaling pathway influences the immune system's ability to fight cancer by examining its effects on both innate and adaptive immune responses. By using mouse models, researchers will investigate the cellular and molecular mechanisms that may reveal new therapeutic targets for enhancing anti-cancer immunity. Patients may benefit from insights that could lead to improved treatment strategies for HCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hepatocellular carcinoma or those at high risk due to chronic liver conditions.
Not a fit: Patients with liver cancer types other than hepatocellular carcinoma may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the immune system's ability to combat liver cancer.
How similar studies have performed: Previous research has shown promising results in targeting immune pathways for cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Koltsova, Ekaterina — Cedars-Sinai Medical Center
- Study coordinator: Koltsova, Ekaterina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.